Decoding Immunotherapy's liver side effect to keep cancer treatment on track
NCT ID NCT06864481
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at liver inflammation (hepatitis) that can occur in cancer patients treated with immune checkpoint inhibitors, a type of immunotherapy. Researchers aim to describe the different patterns of liver injury and how they respond to treatment. By collecting real-world data from 250 adult patients, the goal is to help doctors make better decisions about managing this side effect and when it might be safe to restart immunotherapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could lead to better guidelines for managing liver side effects from immunotherapy and safer decisions about restarting cancer treatment.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test a new therapy. Results may not apply to all patients or cancer types.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER PATIENTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Montpellier University Hospital
RECRUITINGMontpellier, 34295, France
Contact Phone: •••-•••-•••• Email: •••••@•••••